Background: Currently, it is a priority to develop prognostic biomarkers that would allow the identification of patients with progressing prostate diseases with a low risk of progression, so that unnecessary treatment and patient burden can be avoided.Objectives: This study aimed to assess the clinical features and concentrations of selected mediators of apoptosis, markers of inflammation, and immunoexpression of Ki67 and selected mediators of inflammation in patients with PCa after prostatectomy procedures and who underwent palliative radiotherapy for bone metastases, as well as patients with benign prostatic hyperplasia (BPH).Methods: A total of 88 patients, including 54 cases with PCa and 34 with BPH, were included. Stage and tumor grades were determined according to Gleason’s grading system. Immunoenzymatic methods were used to determine apoptotic and inflammatory mediators in serum, as well as deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL) reaction, and immunohistochemistry to determine selected markers of inflammation and Ki67 expression.Results: Strong differentiating indicators were revealed, such as Ki67, and tumor necrosis factor receptor 2. Ki-67 expression was significantly associated with the Gleason score. In turn, the tumor necrosis factor receptor 2 (TNFRII) showed the highest expression in the inflammatory environment of cancer in the metastatic stage.Conclusions: Ki67 and TNFRII can be classified as high-value clinical markers. These factors may be treated as markers regarding future information about the implementation or withdrawal of more aggressive treatment to possibly avoid toxic complications associated with both increased doses in radiotherapy and prolonged hormonal therapy.
背景：当前，开发能够识别前列腺疾病进展风险较低患者的预后生物标志物是优先任务，以避免不必要的治疗和减轻患者负担。 目的：本研究旨在评估前列腺癌（PCa）患者在前列腺切除术后及接受骨转移姑息性放疗后的临床特征、选定凋亡介质浓度、炎症标志物水平，以及Ki67和选定炎症介质的免疫表达情况，并与良性前列腺增生（BPH）患者进行比较。 方法：共纳入88例患者，其中PCa患者54例，BPH患者34例。肿瘤分期与分级依据格里森评分系统确定。采用免疫酶法检测血清中的凋亡与炎症介质，运用脱氧核苷酸末端转移酶介导的dUTP缺口末端标记（TUNEL）反应及免疫组织化学法检测选定的炎症标志物和Ki67表达。 结果：研究揭示了具有强区分度的指标，如Ki67和肿瘤坏死因子受体2。Ki67表达与格里森评分显著相关。而肿瘤坏死因子受体2（TNFRII）在转移期癌症的炎症微环境中呈现最高表达水平。 结论：Ki67与TNFRII可归类为高价值临床标志物。这些因子可作为指导未来治疗决策的标记物，有助于判断是否实施或撤除更积极的治疗方案，从而可能避免因放疗剂量增加或激素治疗延长导致的毒性并发症。
肿瘤(癌症)患者之家